相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer
Marco A. De Velasco et al.
CARCINOGENESIS (2014)
Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
M. Dror Michaelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Hua Yu et al.
NATURE REVIEWS CANCER (2014)
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice
Dipti K. Pawaskar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
Ymera Pignochino et al.
CLINICAL CANCER RESEARCH (2013)
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
Rhonda L. Bitting et al.
ENDOCRINE-RELATED CANCER (2013)
Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
Arnoud J. Templeton et al.
EUROPEAN UROLOGY (2013)
Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
Mari Nakabayashi et al.
BJU INTERNATIONAL (2012)
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models
Barbara Mariniello et al.
ENDOCRINE-RELATED CANCER (2012)
Effects of Sorafenib on C-Terminally Truncated Androgen Receptor Variants in Human Prostate Cancer Cells
Friedemann Zengerling et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Role and Regulation of STAT3 Phosphorylation at Ser727 in Melanocytes and Melanoma Cells
Masanobu Sakaguchi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
Anne-Christine Piguet et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Tumor angiogenesis: molecular pathways and therapeutic targets
Sara M. Weis et al.
NATURE MEDICINE (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer
Jeanny B. Aragon-Ching et al.
BJU INTERNATIONAL (2009)
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2009)
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma
Hung Huynh et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
Pippa Newell et al.
JOURNAL OF HEPATOLOGY (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
Pilot study of rapamycin in patients with hormone-refractory prostate cancer
Robert J. Amato et al.
CLINICAL GENITOURINARY CANCER (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation
Atsushi Tomioka et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
ERK1/2 MAP kinases in cell survival and apoptosis
Zhimin Lu et al.
IUBMB LIFE (2006)
The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer
WR Berry
UROLOGY (2005)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells
L Yang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
JR Grandis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
